Lv7
4940 积分 2021-06-04 加入
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
2个月前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
2个月前
已完结
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
2个月前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
2个月前
已完结
Prostate cancer statistics, 2025
3个月前
已完结
前列腺癌新辅助治疗与辅助治疗的现状及进展
6个月前
已完结
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
7个月前
已完结
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
7个月前
已完结
Advanced Prostate Cancer: Treatment Advances and Future Directions
8个月前
已完结
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
9个月前
已完结
皖公网安备34019202002308
